Diabetes drug may also protect bones, early trial hints
NCT ID NCT06050577
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether oral semaglutide (Rybelsus), a drug already used for type 2 diabetes, can improve bone health in people aged 50-85 with diabetes and weak bones (osteopenia). Over 52 weeks, 64 participants will receive either the drug or a placebo. Researchers will measure bone formation and breakdown markers, bone density, and bone strength to see if the drug shifts the balance toward stronger bones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral semaglutide (Rybelsus)
What this could lead to
If it works, this could point toward a treatment that helps people with type 2 diabetes maintain stronger bones and reduce fracture risk.
What could go wrong
This is a small, early-phase trial with only 64 participants. The results may not apply to everyone, and the bone benefits might be too small to matter in practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Odense University Hospital
Odense, 5000, Denmark